A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3)
I4V-MC-JAHN - ClinicalTrials.gov - NCT03334435
The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis (eczema).
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Atopic DermatitisWhat the trial is testing?
Baricitinib, PlaceboCould I receive a Placebo?
YesEnrollment Goal
1645Trial Dates
Mar 28, 2018 - Jul 12, 2023How long will I be in the trial?
Your participation could last up to 108 weeks and include up to 17 visits to the study center.Trial Phase
IIIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have met participation requirements for a previous atopic dermatitis (eczema) study
Participants must have completed the final treatment visit in a previous baricitinib atopic dermatitis (eczema) study
Participants Must Not:
Participants must not have permanently stopped taking baricitinib during a previous baricitinib study
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo